{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T22:08:13Z","timestamp":1775340493269,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T00:00:00Z","timestamp":1519430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s11239-018-1635-0","type":"journal-article","created":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T06:57:49Z","timestamp":1519455469000},"page":"423-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combining oral anticoagulation and antiplatelet therapies: appropriate patient selection"],"prefix":"10.1007","volume":"45","author":[{"given":"Jeremy W.","family":"Vandiver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Diane Beavers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,24]]},"reference":[{"issue":"2","key":"1635_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jacc.2014.10.035","volume":"65","author":"RS Hira","year":"2015","unstructured":"Hira RS, Kennedy K, Nambi V et al (2015) Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry\u2019s Practice Innovation and Clinical Excellence registry. J Am Coll Cardiol 65(2):111\u2013121","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1635_CR2","doi-asserted-by":"publisher","first-page":"1300-5.e2","DOI":"10.1016\/j.amjmed.2015.05.044","volume":"128","author":"GD Barnes","year":"2015","unstructured":"Barnes GD, Lucas E, Alexander GC, Goldberger ZD (2015) National trends in ambulatory oral anticoagulant use. Am J Med 128(12):1300-5.e2","journal-title":"Am J Med"},{"issue":"7181","key":"1635_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nature06797","volume":"451","author":"N Mackman","year":"2008","unstructured":"Mackman N (2008) Triggers, targets and treatments for thrombosis. Nature 451(7181):914\u2013918","journal-title":"Nature"},{"key":"1635_CR4","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1136\/heartjnl-2014-305486","volume":"100","author":"R Caterina De","year":"2014","unstructured":"De Caterina R, Ammentorp B, Darius H et al (2014) Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart 100:1625\u20131635","journal-title":"Heart"},{"issue":"26","key":"1635_CR5","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"R Bauersachs","year":"2010","unstructured":"Bauersachs R, Berkowitz SD, Brenner B et al (2010) Rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499\u20132510","journal-title":"N Engl J Med"},{"issue":"14","key":"1635_CR6","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"HR B\u00fcller","year":"2012","unstructured":"B\u00fcller HR, Prins MH, Lensin AW et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287\u20131297","journal-title":"N Engl J Med"},{"issue":"9","key":"1635_CR7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"A Agnelli","year":"2013","unstructured":"Agnelli A, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369(9):799\u2013808","journal-title":"N Engl J Med"},{"issue":"12","key":"1635_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, EZekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139\u20131151","journal-title":"N Engl J Med"},{"key":"1635_CR9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffery KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891","journal-title":"N Engl J Med"},{"key":"1635_CR10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"issue":"11","key":"1635_CR11","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.amjmed.2016.05.041","volume":"129","author":"ME Barra","year":"2016","unstructured":"Barra ME, Fanikos J, Connors JM et al (2016) Evaluation of dose-reduced direct oral anticoagulant therapy. Am J Med 129(11):1198\u20131204","journal-title":"Am J Med"},{"issue":"4","key":"1635_CR12","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1378\/chest.07-2627","volume":"133","author":"SG Johnson","year":"2008","unstructured":"Johnson SG, Rogers K, Delate T, Witt DM (2008) Outcomes associated with combined antiplatelet and anticoagulant therapy. Chest 133(4):948\u2013954","journal-title":"Chest"},{"issue":"7","key":"1635_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1161\/CIRCULATIONAHA.113.002927","volume":"128","author":"BA Steinberg","year":"2013","unstructured":"Steinberg BA, Kim S, Piccini JP et al (2013) Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation 128(7):721\u2013728","journal-title":"Circulation"},{"issue":"1","key":"1635_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11239-016-1425-5","volume":"43","author":"CH So","year":"2017","unstructured":"So CH, Eckman MH (2017) Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. J Thromb Thrombolysis 43(1):7\u201317","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"1635_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/archinte.167.2.117","volume":"167","author":"F Dentali","year":"2007","unstructured":"Dentali F, Douketis JD, Lim W, Crowther M (2007) Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 167(2):117\u2013124","journal-title":"Arch Intern Med"},{"issue":"9706","key":"1635_CR16","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","volume":"374","author":"R Sorensen","year":"2009","unstructured":"Sorensen R, Hansen ML, Abildstrom SZ et al (2009) Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374(9706):1967\u20131974","journal-title":"Lancet"},{"issue":"19","key":"1635_CR17","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"AJ Camm","year":"2010","unstructured":"Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31(19):2369\u20132429","journal-title":"Eur Heart J"},{"issue":"20","key":"1635_CR18","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1056\/NEJMoa011258","volume":"345","author":"JP Mohr","year":"2001","unstructured":"Mohr JP, Thompson JLP, Lazar RM et al (2001) A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345(20):1444\u20131451","journal-title":"N Engl J Med"},{"issue":"13","key":"1635_CR19","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa020496","volume":"347","author":"M Hurlen","year":"2002","unstructured":"Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002) Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347(13):969\u2013974","journal-title":"N Engl J Med"},{"issue":"3","key":"1635_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa065959","volume":"357","author":"S Anand","year":"2007","unstructured":"Anand S, Yusuf S, Xie C et al (2007) Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357(3):217\u2013227","journal-title":"N Engl J Med"},{"issue":"9921","key":"1635_CR21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955\u2013962","journal-title":"Lancet"},{"issue":"12","key":"1635_CR22","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.amjcard.2013.08.027","volume":"112","author":"R Artang","year":"2013","unstructured":"Artang R, Rome E, Nielsen JD, Vidaillet HF (2013) Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol 112(12):1973\u20131979","journal-title":"Am J Cardiol"},{"key":"1635_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11239-015-1319-y","volume":"41","author":"DM Witt","year":"2016","unstructured":"Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE (2016) Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis 41:187\u2013205","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"1635_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest (149(2):315\u2013352","journal-title":"Chest"},{"issue":"4","key":"1635_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","volume":"35","author":"JH Alexander","year":"2014","unstructured":"Alexander JH, Lopes RD, Thomas L et al (2014) Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 35(4):224\u2013232","journal-title":"Eur Heart J"},{"key":"1635_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ahj.2016.05.019","volume":"179","author":"R Shah","year":"2016","unstructured":"Shah R, Hellkamp A, Lokhnygina Y et al (2016) Use of concomitant aspirin in patients with atrial fibrillation: findings from the ROCKET AF trial. Am Heart J 179:77\u201386","journal-title":"Am Heart J"},{"issue":"22","key":"1635_CR27","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/eurheartj\/eht049","volume":"34","author":"J Oldgren","year":"2013","unstructured":"Oldgren J, Wallentin L, Alexander JH et al (2013) New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 34(22):1670\u20131680","journal-title":"Eur Heart J"},{"key":"1635_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002587","author":"H Xu","year":"2016","unstructured":"Xu H, Ruff CT, Giugliano RP et al (2016) Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 Trial. J Am Heart Assoc. \n                    https:\/\/doi.org\/10.1161\/JAHA.115.002587","journal-title":"J Am Heart Assoc"},{"issue":"2 Suppl","key":"1635_CR29","first-page":"e576Se600S","volume":"141","author":"RP Whitlock","year":"2012","unstructured":"Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. (2012) Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e576S\u2013e600S","journal-title":"Chest"},{"issue":"6","key":"1635_CR30","first-page":"667","volume":"16","author":"A Colli","year":"2007","unstructured":"Colli A, Mestres CA, Castella M, Gherli T (2007) Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis 16(6):667\u2013671","journal-title":"J Heart Valve Dis"},{"issue":"5","key":"1635_CR31","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.ejcts.2004.12.064","volume":"27","author":"JI Aramendi","year":"2005","unstructured":"Aramendi JI, Mestres CA, Martinez-Leon J et al (2005) Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement: prospective, randomized, co-operative trial. Eur J Cardiotherac Surg 27(5):854\u2013860","journal-title":"Eur J Cardiotherac Surg"},{"issue":"5","key":"1635_CR32","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/0735-1097(94)00563-6","volume":"25","author":"M Heras","year":"1995","unstructured":"Heras M, Chesebro JH, Fuster V et al (1995) High risk of thrombemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 25(5):1111\u20131119","journal-title":"J Am Coll Cardiol"},{"issue":"7329","key":"1635_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"C Baigent","year":"2002","unstructured":"Baigent C, Sudlow C, Collins R (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71\u201386","journal-title":"BMJ"},{"issue":"2 Suppl","key":"1635_CR34","first-page":"e669Se690s","volume":"141","author":"P Alonso-Coello","year":"2012","unstructured":"Alonso-Coello P, Bellmunt S, McGorrian C et al. (2012) Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e669S\u2013e690s","journal-title":"Chest"},{"issue":"6","key":"1635_CR35","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2310\/6670.2004.00043","volume":"12","author":"WC Johnson","year":"2004","unstructured":"Johnson WC, Williford WO, Corson JD, Padberg FT Jr (2004) Hemorrhagic complications during long-term postoperative warfarin administration in patients undergoing lower extremity arterial bypass surgery. Vascular 12(6):362\u2013368","journal-title":"Vascular"},{"issue":"21","key":"1635_CR36","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","volume":"33","author":"AJ Camm","year":"2012","unstructured":"Camm AJ, Lip GY, De Caterina R et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33(21):2719\u20132747","journal-title":"Eur Heart J"},{"issue":"9327","key":"1635_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0140-6736(02)09409-6","volume":"360","author":"RF Es van","year":"2002","unstructured":"van Es RF, Jonker JJ, Verheugt FW et al (2002) Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360(9327):109\u2013113","journal-title":"Lancet"},{"issue":"5","key":"1635_CR38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","volume":"27","author":"F Andreotti","year":"2006","unstructured":"Andreotti F, Testa L, Biondi-Zoccai CG, Crea F (2006) Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 27(5):519\u2013526","journal-title":"Eur Heart J"},{"issue":"12","key":"1635_CR39","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.amjcard.2007.01.052","volume":"99","author":"L Testa","year":"2007","unstructured":"Testa L, Zoccai GB, Porto I et al (2007) Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. Am J Cardiol 99(12):1637\u20131642","journal-title":"Am J Cardiol"},{"issue":"1","key":"1635_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40119-013-0015-2","volume":"2","author":"ET Carreras","year":"2013","unstructured":"Carreras ET, Mega JL (2013) Balancing antiplatelet and anticoagulant therapies in patients with cardiovascular disease. Cardiol Ther 2(1):85\u201396","journal-title":"Cardiol Ther"},{"issue":"14","key":"1635_CR41","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377(14):1319\u20131330","journal-title":"N Engl J Med"},{"key":"1635_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx419","author":"M Valgimigli","year":"2017","unstructured":"Valgimigli M, Beuno H, Byrne RA et al (2017) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehx419\n                    \n                  .","journal-title":"Eur Heart J"},{"issue":"9872","key":"1635_CR43","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJ Dewilde","year":"2013","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW et al (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381(9872):1107\u20131115","journal-title":"Lancet"},{"issue":"25","key":"1635_CR44","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C et al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375(25):2423\u20132434","journal-title":"N Engl J Med"},{"issue":"16","key":"1635_CR45","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J et al (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377(16):1513\u20131524","journal-title":"N Engl J Med"},{"issue":"23","key":"1635_CR46","doi-asserted-by":"publisher","first-page":"e199e267","DOI":"10.1161\/CIR.0000000000000040","volume":"130","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS et al (2014) 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130(23):e199\u2013e267","journal-title":"Circulation"},{"issue":"4","key":"1635_CR47","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.116.025783","volume":"135","author":"CM Gibson","year":"2017","unstructured":"Gibson CM, Pinto DS, Chi G et al (2017) recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy. Circulation 135(4):323\u2013333","journal-title":"Circulation"},{"issue":"10","key":"1635_CR48","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA et al (2016) 2016 ACC\/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol 68(10):1116\u20131139","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1635_CR49","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/phar.1884","volume":"37","author":"SE Conway","year":"2017","unstructured":"Conway SE, Hwang AY, Ponte CD, Gums JG (2017) Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know. Pharmacotherapy 37(2):236\u2013248","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1635_CR50","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11239-009-0413-4","volume":"29","author":"MP Donadini","year":"2010","unstructured":"Donadini MP, Douketis JD (2010) Combine warfarin-aspirin therapy: what is the evidence? J Thromb Thrombolysis 29(2):208\u2013213","journal-title":"J Thromb Thrombolysis"},{"key":"1635_CR51","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","volume":"45","author":"WN Kernan","year":"2014","unstructured":"Kernan WN, Ovbiagele B, Black HR et al (2014) Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 45:2160\u20132236","journal-title":"Stroke"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-018-1635-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1635-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1635-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,24]],"date-time":"2019-02-24T00:26:40Z","timestamp":1550968000000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-018-1635-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,24]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["1635"],"URL":"https:\/\/doi.org\/10.1007\/s11239-018-1635-0","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,24]]},"assertion":[{"value":"24 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Neither Dr. Vandiver or Dr. Beavers have any conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}